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Etude comparative de l'lmmunofluorescence (IF), Enzyme-lmmuno Assay (EIA) et 
Multiplexed Bead-Based Assay (BBA) dans le diagnostic sérologique d'Epstein-Barr 
Virus 
Dans cette étude, nous avons testé la performance diagnostique d'une nouvelle technique 
d'analyse multiplexée qui permet la détection d'anticorps de différentes spécificités dans la 
même réaction. En l'absence de gold standard, nous avons choisi de comparer la 
performance diagnostique de l'analyse avec deux méthodes de référance que sont l'IF et 
EIA, et avec un consensus déterminé selon une règle de majorité entre les trois méthodes. 
393 sérums analysés par IF, conservés par congélation, ont été décongelés pour être 
analysés par EIA et BBA. Pour chaque sérum, les anticorps recherchés ont été les anti-VCA 
(Viral Capsid Antigen) lgM, anti-VCA lgG et anti-EBNA (Epstein-Barr Nuclear Associated) 
lgG. Les échantillons ont été classés en cinq groupes selon les résultats de l'IF : 
séronégatifs, infections aiguës, infections anciennes et deux types d'indéterminés. 
Pour chaque méthode, le résultat numérique (index ou titre) des analyses est converti en 
termes de positif, négatif ou douteux. Pour le résultat de chaque type d'anticorps, un 
consensus est établi selon une règle de majorité entre les trois méthodes, permettant une 
interprétation du stade de l'infection. Puis l'interprétation de chacune des méthodes a été 
comparée au consensus. Nous avons également comparé les trois méthodes les unes aux 
autres concernant la détection des anticorps. 
Globalement, nous observons une bonne corrélation qualitative entre les trois approches 
pour détecter les anti-VCA lgG et lgM. Pour pour les anti-EBNA lgG, il y a une divergence 
notable entre l'IF et les deux autres méthodes, l'IF apparaissant moins sensible que les 
autres méthodes, résultant en un nombre accru d'interprétations indéterminées du stade de 
l'infection. 
L'origine de cette divergence ne peut être due à une perte d'anticorps liée au stockage de 
longue durée des échantillons. En effet, EIA et BBA restent plus sensibles que IF, dont 
l'analyse a été faite sur des sérums frais. 
Cette divergence ne semble pas non plus être due aux différents antigènes utilisés par les 
trois méthodes. EIA et BBA utilisent le même antigène recombinant EBNA-1, alors que l'IF 
utilise des "cellules lymphoïdes choisies pour leur production sélective d'antigènes EBNA". 
Ces cellules sont probablement des cellules infectées par EBV qui devraient exprimer plus 
d'antigènes de latence que seul EBNA-1. Cette différence devrait donc plutôt en principe 
résulter en une meilleure sensibilité de l'IF par rapport aux deux autres méthodes. 
Les anti-EBNA lgG peuvent disparaître chez les patients immunocompromis chez qui se 
produit une réactivation d'EBV. Nous avons donc recherché le status immunitaire des 
patients du groupe dont les sérums étaient négatifs pour anti-EBNA lgG en IF et positifs par 
les autres méthodes: seulement 28 des 70 patients étaient immunocompromis. 
Par conséquent, il est probable que dans la majorité de ces résultats discordants, les 
anticorps anti-EBNA lgG détectés par BBA et EIA sont de vrais positifs non décelés par l'IF. 
En conclusion, BBA est meilleur que la méthode de référance qu'est l'IF, et est égal à EIA en 
ce qui concerne la performance diagnostique. En outre, ces deux nouvelles méthodes offrent 
une économie de temps en raison de manipulations moindres, et ne requièrent aucune 
formation en microscopie à fluorescence. Elles sont également plus économes en 
échantillons que IF. BBA a l'avantage de n'avoir besoin que de deux analyses pour donner 
un diagnostique, alors que IF et EIA ont en besoin d'une par anticorps. Enfin, BBA dispose 
de contrôles internes permettant de reconnaître les liaisons non antigène-spécifiques des 
anticorps. Par contre, BBA nécessite l'achat d'un lecteur par cytométrie de flux assez 
coûteux. 
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Epstein-Barr virus (EBV) is a gamma-herpesvirus that trans-
mits readily in humans, mostly by the oral route, infecting 
more than 95% of the population worldwide [ 1]. After a pri-
mary infection, either asymptomatic or manifesting as an 
infectious mononucleosis and characterized by viral replica-
tion in the oropharynx and in B lymphocytes, EBV-specific T 
cells responses curtail viral replication. The virus DNA then 
persists as an episomal DNA genome in memory B lympho-
cytes, with a very minimal gene expression, described as 
a latent infection. Latent infection is related to lymphopro-
liferative and other malignant diseases in a complex manner 
[2]. 
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The diagnosis of the various stages of EBV infection and of 
EBV-related malignant conditions is partly based on the 
detection of different classes of antibodies specific for vari-
ous EBV antigens [the lytic viral capsid antigens (VCAs), the 
latency-associated Epstein-Barr nuclear antigens (EBNAs) 
and the replicative early antigens (EAs)] [3]. Multiplexed 
assays offer the opportunity to assess antibody responses to 
a panel of antigens in a single, specimen-sparing assay, with 
reduced time requirements. We therefore compared the 
diagnostic performance of the Athena Multi-Lyte® multi-
plexed bead-based assay (BBA) for the detection of EBV-
specific antibodies with the monoplexed immunofluorescence 
assay (IFA) and enzyme immunoassay (EIA). 
Patier.t samples 
A total of 393 serum samples received in the serology labo-
ratory of the lnstitute of Microbiology, Centre Hospitalier 
Universitaire Vaudois, for EBY testing by IFA between 1998 
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and 2005 were included in the study. The sample population 
included adult and paediatric specimens and a mix of speci-
mens from immunocompromised (e.g. solid organ transplant) 
patients and those suspected of acute or latent EBV 
infection. 
The serum samples were classified into five groups 
according to their IFA serostatus pattern: (i) 1 OO non-
infected (seronegative, anti-VCA lgM-, anti-VCA lgG- and 
anti-EBNA lgG-); (ii) 1 OO with acute infection (anti-VCA 
lgM+, anti-VCA lgG+/- and anti-EBNA lgG-, only 94 of 
which were available for analysis by multiplexed BBA); (iii) 
100 with past infection (anti-VCA lgM-, anti-VCA lgG+ and 
anti-EBNA lgG+); (iv) 70 with type 1 indeterminate pattern, 
possibly immunocompromised patients who had lost or not 
developed responses against EBNAs or, rarely, acute 
infection in the absence of anti-VCA lgM (anti-VCA lgM-, 
anti-VCA lgG+ and anti-EBNA lgG-); (v) 23 with type Il 
indeterminate pattern, possibly sub-acute infection or reacti-
vation (anti-VCA lgM+, anti-VCA lgG+ and anti-EBNA lgG+). 
The samples had been stored in the temperature range -20° 
to -40°C from the time of IFA testing and were centrifuged 
for 5 min at 8000 g to remove protein aggregates after 
thawing before testing by multiplexed BBA and EIA. 
EBV-specific antibody testing 
For each serum, the antibodies assayed were: anti-VCA lgM, 
anti-VCA lgG and anti-EBNA lgG. The anti-EA lgG was 
tested only in the BBA. 
The serum samples had initially been analyzed by IFA 
(Merifluor®), anti-EBV lgM and lgG IFNIFT (Meridian Biosci-
ence, Cincinnati, OH, USA) and anti-EBNA ACIF (Focus 
Technologies, Herndon, VA, USA), in accordance with the 
manufacturers' instructions [4]. Sixty microliters of serum 
were used to analyse the three antibodies. HR 1 cells 
expressing the VCA antigen were used in the anti-VCA lgG 
and lgM test kit [3,4]. According to the manufacturer, the 
antigen used in the anti-EBNA lgG kit comprises 'lymphoid 
cells chosen for their selective production of EBNA antigen'. 
Anti-VCA lgM was tested at a single 1 : 10 dilution in IFA 
and samples were arbitrarily assigned a 1 : 5 titre if negative 
and 1 : 20 if positive. 
The samples were then analyzed by EIA (Novitec® EBV-
EIA; Genbio, San Diego, CA, USA) and BBAs were per-
formed on a Luminex 1 OO reader (Athena Multi-Lyte EBV 
lgG and lgM; Zeus Scientific, Raritan, NJ, USA), in accor-
dance with the manufacturer's instructions. ln the EIA, 10 pl 
of serum were diluted and used to analyse the three 
antibodies for each sample. The VCA antigen comprised 
affinity-purified gp 125 VCA from a glycine extract of lysates 
of EBV-infected cells (lgG and lgM) in EIA and BBA, whereas 
-~~--------"----"--~~--"--- -~--
the EBNA antigen was a recombinant EBNA-1 expressed in 
a baculovirus system for EIA and expressed in Escherichia coli 
for BBA. ln the BBA, 10 11L serum were used for the three 
lgG assays and 1 0 pl were used for the lgM test. The BBA 
has built-in controls that assess the binding of antibodies to 
beads not coated with antigen (nonspecific coating; NSC), to 
minimize the false positive results. 
Rheumatoid factor 
To test the effect of rheumatoid factor on the results of 
anti-VCA lgM by BBA, 46 prospective routine sera that gave 
an NSC alarm (see above) for lgM were studied. Rheumatoid 
factor was assayed by nephelometry using the N Latex RF 
kit (Dade Behring, Eschborn, Germany). ln addition, 10 11L of 
serum were diluted in 200 11L of sample diluent containing 
Fc-specific anti-lgG goat antiserum (Sample diluent 005M; 
Zeus Scientific) and centrifuged for 5 min at 8000 g to 
remove lgG. The supernatant was used in the BBA as 
described above. 
Serostatus interpretation 
For each method, the dilution or index value was translated 
into positive, negative or indeterminate qualitative results, in 
accordance with the manufacturer's instructions. 
T o compare the diagnostic interpretations of the three 
methods, a consensus interpretation was established for each 
antibody response using a majority rule. The consensus was 
defined as the majority interpretation if two out of three or 
three out of three assays produced the same antibody inter-
pretation. There was therefore no defined consensus when 
all three results were different (or when one of the assays 
produced an uninterpretable result; e.g. when the BBA gave 
an undefined result such as NSC and the two others gave 
discordant results). The anti-EA antigen was available only 
with the BBA and therefore was not included in this analysis. 
The stages of the infection were defined according to the 
presence of the various antibodies as suggested by Hess [3] 
(Table 1 ). Each serum specimen was attributed a serostatus 
Classification of Epstein-Barr virus infection stage 
according to serostatus pattern 
VCA lgM VCA lgG EBNAlgG 
Acute infection + +/-
Past infection + + 
Seronegative 
lndeterminate 1 + 
lndeterminate Il + + + 
Non plausible + 
VCA, viral capsid antigen; EBNA, Epstein-Barr nuclear antigen. 
©2010 The Authors 
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interpretation by each method and by consensus, and each 
assay serostatus interpretations were compared with the 
consensus interpretation. 
Statistical analysis 
The quantitative relationship between antibody titres and 
indices was evaluated by linear regression using STATA 10 
software (StataCorp, College Station, TX, USA) on log-trans-
formed values. 
Ethical considerations 
The present study was performed using samples left over 
from clinically motivated EBV testing of patients who had 
given consent with respect to their potential use for 
research and development. This procedure was approved by 
the local research ethics committee. 
For each antigen-specific antibody, the results of the three 
methods were compared (Fig. 1 ). 
Anti-VCA lgM 
Fig. 1 (upper left) shows the relationship for anti-VCA lgM 
assessed by EIA and IFA. There was generally a good qualita-
tive concordance (364/393; 93%) between these two tests 
when classified as negative/indeterminate/positive. EIA 
appeared somewhat less sensitive than IFA, with 21 discor-
dant samples (IFA positive/EIA negative). Because IFA testing 
for anti-VCA lgM was run only qualitatively at a single 1 : 10 
dilution, this precluded a quantitative comparison with EIA 
and BBA indices. 
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For each antibody type, the three methods were compared with each other. The lower left (negative) and upper right (positive) 
quadrants contain concordant data with the corresponding number of sera shown. The upper left and lower right quadrants show discor-
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Fig. 1 (middle left) shows the relationships of anti-VCA 
lgM results assessed by BBA and IFA. The smaller number of 
data points is principally due to invalid NSC results in the 
BBA. There was a good qualitative concordance (329/350; 
94%) between these two tests. BBA had a sensitivity for 
anti-VCA lgM intermediate between IFA and EIA, with only 
ten discordant samples (IFA positive/BBA negative). 
Finally, Fig. 1 (lower left) shows the qualitative concor-
dance between BBA and EIA indices (328/350; 94%) among 
the 350 sera for which pairs of results were available. Both 
EIA and BBA results were expressed as quantitative indices 
and were highly correlated (r = 0.83). 
With the BBA, 46 of 393 samples (among which 36 were 
NSC for anti-VCA lgM and ten for anti-VCA and anti-EBNA 
lgG) gave NSC results. The 46 selected sera had detectable 
rheumatoid factor by nephelometry and gave NSC results 
for anti-VCA lgM in the initial testing, but had no NSC 
results when retested after absorption, with 42 of them 
being negative and four being positive for anti-VCA lgM. 
Anti-VCA lgG 
Fig. 1 (upper central) shows the relationship between the 
anti-VCA lgG results obtained with EIA and IFA. There was 
good qualitative concordance (361 /393; 92%) but no quanti-
tative correlation (r = 0.10). Fig. 1 (middle central) panel 
shows the relationship between the anti-VCA lgG results 
obtained with BBA and IFA. There was again a good qualita-
tive concordance (347/375; 93%) and a somewhat better 
Comparison of immunofluorescence assay and 
consensus interpretations 
lmmunofluorescence assay 
Non- Acute Past 
Consensus infected infection infection lndeterminate Total 
Non-infected 85 85 
Acute infection 82 3 85 
Past infection 5 96 56 157 
lndeterminate 3 2 3 23 JI 
Non plausible 2 2 
No consensus 5 10 1 Il 27 
Total 100 94 100 93 387 
quantitative correlation (r2 = 0.37). Finally, Fig. 1 {lower cen-
tral) shows the good qualitative concordance between the 
BBA and EIA results (340/375; 91 %) but no quantitative cor-
relation (r2 = 0.08). 
Anti-EBNA lgG 
Fig. 1 (upper right) shows the relationship between the anti-
EBNA lgG results obtained with EIA and IFA. There was a 
low qualitative concordance (300/393; 76%) compared to 
anti-VCA lgM and anti-VCA lgG tests and again no obvious 
quantitative correlation (r = 0.1 1 ). Fig. 1 (middle right) 
shows the relationship between the anti-EBNA lgG results 
obtained by BBA and IFA. There was a low qualitative con-
cordance (278/373; 75%) and again no obvious quantitative 
correlation (r2 = 0.16). Finally, Fig. 1 (lower right) shows a 
relatively high qualitative (330/373; 88%) and quantitative 
(r2 = 0.44).concordance between the the BBA and EIA 
results. 
Comparison of serostatus interpretations 
Table 2 shows the comparison between IFA and consensus 
interpretations of the stage of infection. There were 286/387 
(73.9%) concordant interpretations and 74/387 ( 19.1 %) dis-
cordant ones, whereas 27/387 (7.0%) samples had no con-
sensus by the majority rule. This relatively low concordance 
was mostly the result of infection classified as indeterminate 
by IFA with the anti-VCA lgG+ and anti-EBNA lgG- serosta-
tus pattern and as past infection by the consensus (due to 
EIA and BBA positive anti-EBNA lgG results). This was the 
case for 56 serum samples. 
Table 3 shows the comparison between EIA interpreta-
tions and the consensus interpretations. There was a better 
concordance (329/387; 85%) with only 18/387 (4.7%) discor-
dant interpretations. For 40 samples ( 10.3%), no comparison 
of interpretations could be made because consensus could 
not be reached or EIA serostatus was indeterminate (grey 
zone result). The relatively low sensitivity of EIA and BBA 
for anti-VCA lgM resulted in a reduced number of acute 
infection interpretations (82, 67 and 72 cases with IFA, EIA 
and BBA, respectively). 
Comparison of enzyme immunoassay and consensus interpretations 
Consensus 
Non-infected 
Acute infection 
Past infection 
lndeterminate 
Non plausible 
No consensus 
Total 
Enzyme immunoassay 
Non-infected Acute infection Past infection lndeterminate Non plausible Grey zone Total 
80 
67 
80 67 
154 
3 
1 
6 
164 
3 
9 
2 
27 
3 
44 
2 85 
9 85 
1 157 
1 31 
2 
18 27 
31 387 
©2010 The Authors 
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Comparison of bead-based assay and consensus interpretations 
Bead-based assay 
Consensus Non-infected Acute infection Past infection 
Non-infected 67 3 
Acute infection 72 
Past infection 135 
lndeterminate 5 
Non plausible 2 
No consensus 1 7 
Total 67 77 150 
NSC, nonspecific coating. 
Table 4 shows the comparison of consensus interpreta-
tions of the BBA. There were 291 /387 (75.2%) concordant 
interpretations but only 28/387 (7.2%) discordant ones. For 
64 samples ( 17.6%), no comparison could be made because 
consensus could not be reached, or because of invalid NSC 
results in the BBA. 
Because there was a substantial discrepancy between IFA 
and the other two methods for the anti-EBNA lgG results, 
we reviewed the clinicat charts of the 70 patients with the 
anti-VCA lgG+, lgM-, anti-EBNA lgG- serostatus pattern 
and found that only 28 of these patients had evidence of 
immunosuppressive conditions or treatment that may explain 
a negative anti-EBNA lgG result in a patient with past infec-
tion. Another cause of discrepancy may be young age. The 
42 patients without immunosuppressive conditions were 
aged from 1 month to 87 years (median 29 years) with a 
25th percentile at 19 years. We also reviewed the BBA anti-
EA lgG results of these 70 patients). Fifty were anti-EA lgG-
negative, ten were positive, seven were in the grey zone and 
lndeterminate Non plausible Grey zone NSC Total 
6 2 5 85 
4 9 85 
2 2 18 157 
17 5 31 
2 
7 2 10 27 
36 4 6 47 387 
three were invalid (two due to NSC), without any obvious 
relationship with the patient's immune status. 
IFA is acknowledged as the reference method in EBV 
serology. We therefore compared the IFA results with those 
of the newer methods (EIA and BBA) (Tables 5 and 6). The 
major difference compared with Tables 3 and 4 is in the clas-
sification of past infections (as defined by EIA and BBA) as 
indeterminate infections by IFA, again indicating a relatively 
low sensitivity of our IFA for anti-EBNA lgG. 
ln the present study, we compared the diagnostic perfor-
mance of a recently developed multiplexed BBA that allows 
the determination of antibody responses to several antigens 
in the same reaction. ln the absence of a gold standard to 
ascertain the status of EBV infection, the diagnostic perfor-
mance of this assay was assessed by comparison with the 
Comparison of enzyme and immunofluorescence assay interpretations 
Enzyme immunoassay 
lmmunofluorescence 
assay Non-infected Acute infection Past infection lndeterminate Non plausible Grey zone 
Non-infected 80 6 6 
Acute infection 65 2 12 
Past Infection 93 5 
lndeterminate 2 63 21 
Total 80 67 164 44 
Comparison of bead-based and immunofluorescence assay interpretations 
lmmunofluorescence 
assay 
Non-infected 
Acute infection 
Past infection 
lndeterminate 
Total 
NSC, nonspecific coating. 
©2010 The Authors 
Bead-based assay 
Non-infected 
67 
67 
Acute infection 
3 
69 
5 
77 
Past infection lndeterminate 
12 7 
10 
81 6 
57 13 
150 36 
Journal Compilation ©201 O European Society of Clinical Microbiology and lnfectious Diseases, CM/, 16, 1776-1782 
7 
15 
2 
7 
31 
Non plausible Grey zone NSC 
2 2 7 
1 14 
1 12 
1 3 14 
4 6 47 
Total 
100 
94 
100 
93 
387 
Total 
100 
94 
100 
93 
387 
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reference methods and with a consensus of the results for 
all three methods determined by a majority rule. Compared 
with previous studies assessing the diagnostic performance of 
similar assays, the present study had more samples that were 
representative of each serostatus pattern determined by IFA 
[5-7]. lt also had immunofluorescence data available for all 
samples, and not just for EIA/BBA discordant results as was 
the case in the study by Binnicker et al. [8]. 
Overall, we observed a good qualitative correlation 
between the three methods for detecting anti-VCA lgG and 
lgM antibodies. Of note, the serum samples had been frozen 
and stored for several years before testing by EIA and BBA, 
although we did not observe a reduced sensitivity for these 
tests compared with IFA that had been performed on fresh 
unfrozen sera. Thus, discrepancies cannot be attributed to 
antibody loss as a result of storage. Another potential source 
for discrepancies could be the use of different antigens in 
these tests. Both EIA and BBA used recombinant gp 125 
VCA, whereas the IFA assay used HR 1 cells that express this 
antigen and other lytic antigens [9]. 
Compared with IFA and EIA, BBA had a slightly reduced 
sensitivity for the detection of anti-VCA lgM, resulting in in 
less frequent interpretations of acute infection. 
By contrast, we observed a clearly reduced sensitivity of 
IFA compared to the two other methods for the detection 
of anti-EBNA antibodies. Although the two latter tests use 
recombinant EBNA-1 as antigens, IFA was performed using 
(in accordance with the manufacturer's instructions) 'lym-
phoid cells chosen for their selective production of EBNA 
antigens'. We could not obtain more details, although it is 
likely that these are latently EBV-infected cells that may 
express more latent antigens than just EBNA-1. If anything, 
this should result in IFA being more sensitive than the other 
assays. Second, anti-EBNA-1 lgG antibodies have been 
decribed as appearing later than other anti-EBNA antibodies 
but with life long persistence [3]. Thus, if the cells used for 
IFA testing expressed little EBNA-1, this would account for 
the apparent lad< of sensitivity of IFA in patients with a pat-
tern otherwise reflecting past infection (anti-VCA lgG+, anti-
VCA lgM-). 
Anti-EBNA lgG antibodies have been reported to disap-
pear during EBV reactivation in immunocompromised 
patients [3, 1 O]. However, among patients with discordant 
anti-EBNA lgG results (in the setting of positive anti-VCA lgG 
and negative lgM), only a minority had a history of immuno-
suppressive conditions, and even less detectable anti-EA anti-
bodies that are a marker for EBV reactivation [3]. Therefore, 
it is likely that, in the majority of discordant results where 
anti-EBNA antibodies were detected by EIA and/or BBA, 
these were true positives in patients with past infection. 
- ---- -----~--- -
lndeterminate (type 1) results might also occasionally 
occur in acute infection in the absence, or after rapid disap-
pearance, of anti-VCA lgM in paediatric patients. However, 
only a minority of our patients were children. We also 
included type Il indeterminate samples (anti-VCA lgM+, anti-
VCA lgG+ and anti-EBNA lgG+) in our study. ln both types 
of indeterminate results, the assessment of anti-VCA lgG 
avidity may be helpful in deciding the stage of infection [3]. 
Finally, we cannot exclude the possibility that these discrep-
ancies are consistant false positive anti-EBNA lgG results 
with EIA and BBA as a result of long-term freezing. 
Titres of anti-VCA lgG assessed by EIA have been 
reported to carry useful information as markers for EBV 
reactivation and correlate with EBV DNA load in the blood 
in various EBV-related malignancies, such as Hodgkin's lym-
phoma [ 1 1] or nasopharyngeal carcinoma [ 12]. lt is impor-
tant in this respect to note the poor quantitative correlation 
between BBA and EIA indices and immunofluorescence 
titres. This suggests that anti-VCA lgG results should not be 
interpreted quantitatively, irrespective of the method used. 
Although our quantitative discrepancies between BBA and 
IFA or EIA and IFA may be ascribed to differences in anti-
gens, it is more difficult to explain the discrepancy between 
BBA and EIA because both are based on the same antigen. 
This lack of correlation may in part be the result of diluted 
samples not being run when samples gave out of range sig-
nais, which occurred in a substantial number of samples, as 
can be seen by the funnelling of dots in the upper right cor-
ner of the graph in Fig. 1 (BBA vs. EIA anti-VCA lgG; lower 
central graph). 
ln any case, the diagnosis of nasopharyngeal carcinoma 
should include testing for primarily lgA directed against vari-
ous EBV antigens by IFA and BBA [13]. 
The concordance of BBA appeared lower than the con-
cordance of EIA with the consensus, although this was 
related to the implementation of an internai control in the 
BBA that detected NSC in samples that may otherwise give 
a false positive result. At the time of the study, the eut-off 
values for NSC were relatively low, leading to the designa-
tion of 58 results as invalid, of which 47 were the result of 
NSC. Forty-four of those sera were available for retesting 
with a new version of the kit (reset threshold and new wash 
buffer). Of those, none tested NSC for lgG and 12 of 44 
remained NSC for lgM. ln addition, this residual problem 
could be solved by the use of an lgG absorption step before 
lgM testing as demonstrated in prospective samples. 
ln conclusion, BBA compared favourably with the refer-
ence IFA and produced similar resuts to the EIA methods. 
Both BBA and EIA offer a substantial saving in time as well 
as sample size ( 10 and 20 fil, respectively, vs. 60 fil for IFA) 
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and do not require training in fluorescence microscopy. 
However, BBA requires only two assays compared to one 
assay per antibody specificity for EIA and IFA. Finally, the 
BBA requires a costly flow cytometry reader. 
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